文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Prognostic Value of Heterogeneity Index Derived from Baseline F-FDG PET/CT in Mantle Cell Lymphoma.

作者信息

Liu Fei, Gu Bingxin, Li Nan, Pan Herong, Chen Wen, Qiao Ying, Song Shaoli, Liu Xiaosheng

机构信息

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Front Oncol. 2022 Apr 14;12:862473. doi: 10.3389/fonc.2022.862473. eCollection 2022.


DOI:10.3389/fonc.2022.862473
PMID:35494037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9047855/
Abstract

OBJECTIVES: Mantle cell lymphoma (MCL) represents a group of highly heterogeneous tumors, leading to a poor prognosis. Early prognosis prediction may guide the choice of therapeutic regimen. Thus, the purpose of this study was to investigate the potential application value of heterogeneity index (HI) in predicting the prognosis of MCL. METHODS: A total of 83 patients with histologically proven MCL who underwent baseline fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) were retrospectively enrolled. The clinicopathologic index and PET/CT metabolic parameters containing maximum and mean standard uptake value (SUV and SUV), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and HI were evaluated. Receiver operating characteristic (ROC) curve analyses were performed to determine the optimal cutoff values of the parameters for progression-free survival (PFS) and overall survival (OS). Univariate and multivariate Cox regression were used to assess relationships between risk factors and recurrence. Kaplan-Meier plots were applied for survival analyses. RESULTS: In univariate analyses, age [HR = 2.51, 95% CI = 1.20-5.24, = 0.041 for body weight (BW)] and HI-BW (HR = 4.17, 95% CI = 1.00-17.38, = 0.050) were significantly correlated with PFS. In multivariate analyses, age (HR = 2.61, 95% CI = 1.25-5.47, = 0.011 for BW) and HI-BW (HR = 4.41, 95% CI = 1.06-18.41, = 0.042) were independent predictors for PFS, but not for OS. B symptoms (HR = 5.00, 95% CI = 1.16-21.65, = 0.031 for BW) were an independent prognostic factor for OS, but not for PFS. The other clinicopathologic index and PET/CT metabolic parameters were not related to outcome survival in MCL. CONCLUSION: The age and HI derived from baseline PET/CT parameters were significantly correlated with PFS in MCL patients.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/1c73f260ec75/fonc-12-862473-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/6d8f15c241e7/fonc-12-862473-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/220b25b7fcd4/fonc-12-862473-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/cb0723f5bc6e/fonc-12-862473-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/1c73f260ec75/fonc-12-862473-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/6d8f15c241e7/fonc-12-862473-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/220b25b7fcd4/fonc-12-862473-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/cb0723f5bc6e/fonc-12-862473-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbc8/9047855/1c73f260ec75/fonc-12-862473-g004.jpg

相似文献

[1]
Prognostic Value of Heterogeneity Index Derived from Baseline F-FDG PET/CT in Mantle Cell Lymphoma.

Front Oncol. 2022-4-14

[2]
Prognostic role of baseline F-FDG PET/CT parameters in MALT lymphoma.

Hematol Oncol. 2018-11-8

[3]
Establishment and validation of a nomogram with intratumoral heterogeneity derived from F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma.

BMC Cancer. 2020-1-15

[4]
Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on F-FDG PET/CT for Patients with Colorectal Cancer.

Contrast Media Mol Imaging. 2022

[5]
[Semiquantitative parameters of F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma].

Beijing Da Xue Xue Bao Yi Xue Ban. 2020-10-20

[6]
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.

Ann Nucl Med. 2019-3-30

[7]
[Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].

Zhonghua Zhong Liu Za Zhi. 2018-7-23

[8]
[Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].

Zhonghua Zhong Liu Za Zhi. 2019-11-23

[9]
Prognostic value of metabolic tumour volume on baseline F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Eur J Nucl Med Mol Imaging. 2019-4-2

[10]
[Prognostic Value of F-FDG PET/CT Metabolic Parameters in Patients with Diffuse Large B-Cell Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021-8

引用本文的文献

[1]
Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study.

J Clin Med. 2024-8-27

[2]
Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.

Sci Rep. 2023-10-24

[3]
PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies.

Cancers (Basel). 2022-11-30

本文引用的文献

[1]
Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.

Cancer Res Treat. 2021-7

[2]
Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma.

Cancer Biol Med. 2020-8-15

[3]
What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?

Hematol Oncol Clin North Am. 2020-10

[4]
Molecular Pathogenesis of Mantle Cell Lymphoma.

Hematol Oncol Clin North Am. 2020-10

[5]
Emerging therapies in mantle cell lymphoma.

J Hematol Oncol. 2020-6-17

[6]
F-FDG PET or PET/CT in Mantle Cell Lymphoma.

Clin Lymphoma Myeloma Leuk. 2020-7

[7]
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.

Blood. 2020-7-30

[8]
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.

Haematologica. 2020-1

[9]
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

Eur J Nucl Med Mol Imaging. 2019-7-25

[10]
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.

Am J Hematol. 2019-4-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索